2B48 Den, Robert B. - Thomas Jefferson University - Thomas Jefferson University
rbd003

Robert B. Den, MD

Contact Dr. Den

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6702
(215) 955-0412 fax

Most Recent Peer-reviewed Publications

  1. The Missing Pieces in Reporting of Randomized Controlled Trials of External Beam Radiation Therapy Dose Escalation for Prostate Cancer
  2. The landscape of prognostic outlier genes in high-risk prostate cancer
  3. Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities
  4. Reply to Nicola Fossati, Giorgio Gandaglia, Alberto Bossi, Francesco Montorsi, Alberto Briganti's Letter to the Editor re: Stephen J. Freedland, Voleak Choeurng, Lauren Howard, et al. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy After Radical Prostatectomy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.01.008
  5. Dosing, administration, and safety of radium-223: How i do it
  6. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy
  7. Novel targeted siRNA-loaded hybrid nanoparticles: Preparation, characterization and in vitro evaluation
  8. Is robotic arm stereotactic body radiation therapy 'virtual high-dose rate brachytherapy' effective for prostate cancer? An analysis of comparative effectiveness using published data
  9. Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis
  10. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy
  11. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer
  12. Uncertainties encountered in implementation of adaptive planning with in vivo dosimeters
  13. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation
  14. Adjuvant versus salvage radiation therapy for prostate cancer patients with adverse pathologic features: Comparative analysis of long-term outcomes
  15. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes
  16. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer
  17. The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness
  18. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy
  19. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation
  20. Practical guide to the use of radium 223 dichloride
0